Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

Abstract Gastrointestinal (GI) malignant neoplasms have a high global incidence and treatment prospects for patients with advanced GI tumors are dismal. PD-1/PD-L1 inhibitors emerged as a frontline treatment for several types of cancer. However, the shortcomings of PD-1/PD-L1 inhibitors have been ob...

Descripció completa

Dades bibliogràfiques

Autors principals:	Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery, Haitao Zhao
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2019-04-01
Col·lecció:	Journal of Hematology & Oncology
Matèries:	Gastrointestinal malignancies PD-1/PD-L1 blockade Immune checkpoint inhibitor Combination immunotherapy Clinical application Rationale
Accés en línia:	http://link.springer.com/article/10.1186/s13045-019-0730-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!